Gland Pharma announced its financial results for the second quarter ended September 30, 2026, showcasing substantial growth. Revenue from operations increased by 23% year-on-year to ₹18,336 million, while profit after tax (PAT) saw a remarkable surge of 58% year-on-year, reaching ₹2,908 million. The company attributed this performance to strong execution across its businesses, particularly the CDMO segment, which grew by 31% year-on-year.
Gland Pharma Reports Robust Q2 FY27 Performance
Gland Pharma Limited has announced its financial results for the second quarter (Q2) and half year ended September 30, 2026. The company has demonstrated strong growth across key financial metrics, highlighting its robust market position and operational efficiency.
Key Financial Highlights
For the second quarter of FY27, Gland Pharma reported a 23% year-on-year (YoY) increase in revenue from operations, amounting to ₹18,336 million. This growth was driven by a strong performance in its core businesses. The company also achieved a significant 58% YoY growth in Profit After Tax (PAT), which stood at ₹2,908 million. The PAT margin for the quarter was 16%.
The company’s Adjusted EBITDA also saw a substantial increase of 50% YoY, reaching ₹5,030 million, with an adjusted EBITDA margin of 27%. Gross Profit grew by 25% YoY to ₹11,638 million.
Half-Yearly Performance
For the first six months of FY27 (6M FY27), Gland Pharma reported a 21% YoY increase in revenue from operations, totaling ₹36,339 million. Profit After Tax for the half year grew by 52% YoY to ₹6,077 million. The adjusted EBITDA for the six-month period increased by 43% YoY to ₹10,132 million.
Business Segment Performance
The company’s business segments showed strong momentum. The CDMO business grew by 31% YoY, contributing 45% of the total revenue. The Critical Injectables business grew by 18% YoY, accounting for 55% of revenues. The company highlighted that CDMO growth was supported by recent product launches and increased volumes, while Critical Injectables growth was driven by new launches and increased demand from existing customers.
Geographical Performance
Geographically, the USA market showed significant growth with a 42% YoY increase in Q2 FY27, contributing 64% to the total revenue in the quarter. Europe also witnessed a healthy 30% YoY growth in Q2 FY27.
Strategic Updates and Outlook
Gland Pharma continues to invest in R&D, with R&D expenses standing at ₹1,077 million in Q2 FY27, representing 6% of consolidated revenue. The company also announced 4 new molecule launches in the USA during the quarter and has a robust pipeline for complex injectables. The company remains well-positioned to capitalize on growing global outsourcing opportunities.
The results were reviewed by the Audit Committee and approved by the Board of Directors on November 6, 2026.
Source: BSE
